Cue Biopharma, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Cue Biopharma, Inc. (CUE) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $29.85 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-14
- Cue Biopharma, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $10.10, a 920.20% increase year-over-year.
- Cue Biopharma, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.99, a 50.99% decline year-over-year.
- Cue Biopharma, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $2.02, a 36.88% decline year-over-year.
- Cue Biopharma, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $3.20, a 54.67% decline year-over-year.
- Cue Biopharma, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $0.82, a 41.84% decline from fiscal 2024.
- Cue Biopharma, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $1.41, a 61.26% decline from fiscal 2023.
- Cue Biopharma, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $3.64, a 47.93% decline from fiscal 2022.
- Cue Biopharma, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $6.99, a 49.64% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $29.85 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | $10.10 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $0.82 10-K · filed 2026-03-16 | |||
| 2025-09-30 | $0.82 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $0.99 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $0.99 10-Q · filed 2025-05-12 | |||
| 2024-12-31 | $1.41 10-K · filed 2026-03-16 | |||
| 2024-09-30 | $1.42 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $1.93 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | $2.02 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $3.64 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $3.65 10-Q · filed 2023-11-03 | |||
| 2023-06-30 | $3.25 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $3.20 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $6.99 10-K · filed 2024-03-28 | |||
| 2022-09-30 | $6.99 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $7.06 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $7.06 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $13.88 10-K · filed 2023-03-21 | |||
| 2021-09-30 | $14.41 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $14.49 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $14.73 10-Q · filed 2021-05-10 | |||
| 2020-12-31 | $17.31 10-K · filed 2022-03-16 | |||
| 2020-09-30 | $17.34 10-Q · filed 2020-11-09 | |||
| 2020-06-30 | $16.49 10-Q · filed 2020-08-07 | |||
| 2020-03-31 | $16.47 10-Q · filed 2020-05-07 | |||
| 2019-09-30 | $6.37 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | $6.33 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $6.33 10-Q · filed 2019-05-08 | |||
| 2018-12-31 | $11.33 10-K · filed 2020-03-12 | |||
| 2018-09-30 | $11.88 10-Q · filed 2018-11-13 | |||
| 2018-06-30 | $13.87 10-Q · filed 2018-08-13 | |||
| 2018-03-31 | $16.65 10-Q · filed 2018-05-14 | |||
| 2017-12-31 | $5.89 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |